Osocimab (BAY 1213790) is a potent anti-FXIa monoclonal antibody, characterized by a dissociation constant (Ki) of 2.4 nM and a half-maximal effective concentration (EC50) of 0.2 nM. This antibody targets Factor XIa (FXIa), a key enzyme in the coagulation cascade, and its inhibition is associated with a reduced risk of thrombosis. Osocimab effectively inhibits thrombin generation and prolongs the activated partial thromboplastin time (aPTT), demonstrating significant anticoagulant properties. This makes it a valuable tool for studies focused on the regulation of blood coagulation and the development of therapeutic strategies for thrombotic disorders.
Osocimab (BAY 1213790) is a potent anti-FXIa monoclonal antibody, characterized by a dissociation constant (Ki) of 2.4 nM and a half-maximal effective concentration (EC50) of 0.2 nM. This antibody targets Factor XIa (FXIa), a key enzyme in the coagulation cascade, and its inhibition is associated with a reduced risk of thrombosis. Osocimab effectively inhibits thrombin generation and prolongs the activated partial thromboplastin time (aPTT), demonstrating significant anticoagulant properties. This makes it a valuable tool for studies focused on the regulation of blood coagulation and the development of therapeutic strategies for thrombotic disorders.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
